We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 39

Court upholds drug profit sharing; pharma co. breached agreement to negotiate deal
  • Shook Hardy & Bacon LLP
  • USA
  • June 7 2012

A Delaware court has issued a letter opinion finalizing its 2011 ruling requiring SIGA Technologies Inc. to share profits from its smallpox drug with PharmAthene, Inc. PharmAthene, Inc. v. SIGA Techs, Inc., No. 267-VCP (Del. Ch., decided May 31, 2012


NASDAQ Biotechnology Index surpasses all-time high in 1Q13
  • Shook Hardy & Bacon LLP
  • USA
  • May 16 2013

The NASDAQ Biotechnology Index reportedly rose in the first quarter of 2013 (1Q13) above levels last seen during the 2000 genomics bubble peakthe


Royalty financing gains favor for VC biotech funding
  • Shook Hardy & Bacon LLP
  • USA
  • August 29 2013

According to a former venture capitalist (VC), a recent deal involving a royalty in exchange for a cash infusion to develop and commercialize a


U.S. biotech sector shows IPO gains in 2013
  • Shook Hardy & Bacon LLP
  • USA
  • June 6 2013

According to Reuters, 14 biotech companies have gone public so far in 2013, marking a possible turnaround for the sector with a rising stock market


Biotech investments rise in Q4 2012, but remain off for the year
  • Shook Hardy & Bacon LLP
  • USA
  • January 24 2013

Pricewatershouse Coopers LLP has released its fourth quarter (Q4) and final 2012 venture capital investment reports and notes that "Biotechnology


Biotech IPO market, booming or bubbling?
  • Shook Hardy & Bacon LLP
  • USA
  • October 17 2013

Speakers at a recent Biotechnology Industry Organization (BIO) Investor Forum in San Francisco reportedly claimed that this year's successes for


Company secures $10 million in venture capital financing to improve DNA sequencing technology
  • Shook Hardy & Bacon LLP
  • USA
  • September 22 2011

NABsys, Inc., a Rhode Island-based developer of electronic systems used for sequencing and analyzing single-molecule DNA, has reportedly raised $10 million in new venture capital funding, closing a Series C preferred stock financing round


Cincinnati investor closes $4.4 million fund to invest in startups
  • Shook Hardy & Bacon LLP
  • USA
  • June 30 2011

Cincinnati-based CincyTech, a venture development company that invests in startup biotech, information technology and advanced manufacturing businesses, has announced the closing of a $4.4 million Fund II targeted for 10 to 12 new startups in southwest Ohio


Financial group analyzes M&A deals in biotech and medical device industries
  • Shook Hardy & Bacon LLP
  • USA
  • June 16 2011

According to an SVP Financial Group report, contrary to conventional wisdom, biotech exits occur faster than device exits and have lower, but solid, multiples on invested capital


Molecular diagnostics company nets $27.7 million from common stock offering
  • Shook Hardy & Bacon LLP
  • USA
  • September 26 2013

Illinois-based Nanosphere, Inc. has reportedly closed a public offering of more than 17 million shares of common stock at $1.75 per share, including